Healthcare
Evotec SE(EVO)
Live Price
Offline$2.62
+2.34% today
1Y Change
-32.69%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $950.00M
- Revenue Growth
- -5.0%
- EPS Growth
- +49.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Evotec SE (EVO) is a Healthcare stock with a market cap of $950.00M and listed on NASDAQ. The stock last traded around $2.62 and down 32.7% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -5.0%, EPS growth of +49.5%, a dividend yield of 0.0%. What stands out right now is revenue -5.0%, EPS +49.5%, free cash flow +30.9% with operating margin -8.6% and ROIC -4.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EVO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-5.0% vs +7.6% peer median
Operating Margin
Below sector median
-8.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 6, 2026 with an EPS surprise of -217.9% and a revenue surprise of +5.0%.
The operating picture looks softer than before
Revenue is at -5.0% and EPS is at +49.5%, with operating margin around -8.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | -217.9% | -5.9% | -16.0% | -8.3% |
2026 Apr 8, 2026 | -74.0% | -2.6% | +19.3% | +20.4% |
2025 Nov 5, 2025 | -1.4% | -1.2% | -6.3% | -3.6% |
Benchmark Edge
EVO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EVO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EVO Max Drawdown
-46.77%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EVO and SPY.
Company Overview
Evotec SE
NASDAQ Global Select
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- Leadership
- Christian Wojczewski
- IPO Date
- Feb 5, 2004
- Employees
- 4.8k
- Street Address
- Essener Bogen 7
- Mailing
- Hamburg, 22419
- Region
- Hamburg, DE
- Reporting Currency
- USD
- Investor Line
- 49 40 560 81 0
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.2
- Price/Book
- 1.2
Growth
- Revenue
- -5.0%
- EPS
- +49.5%
- Free Cash Flow
- +30.9%
Profitability
- Gross Margin
- 14.5%
- Operating Margin
- -8.6%
- Net Margin
- -13.1%
- ROE
- -12.3%
- ROIC
- -4.5%
Balance Sheet
- Debt/Equity
- 0.55
- Current Ratio
- 2.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.